Octreotide: Supply issue resolved
The supplier of the funded octreotide 50 mcg and 500 mcg per ml injections (Pfizer) was experiencing issues with the supply of this medicine.
4 February 2021 update
Pfizer has advised that funded funded octreotide 50 mcg and 500 mcg per ml injections are back in stock. They will be supplied once stocks of the alternative brands are depleted.
To ensure continuity of supply, Pfizer has sourced alternatives.
These were listed from 1 September 2020
- Octreotide GH inj 50 mcg per ml, 1 ml ampoule (Pharmacode 2595907)
- Octreotide GH inj 500 mcg per ml, 1 ml ampoule (Pharmacode 2595893)
Pfizer advises that these products can be ordered from OneLink.
These products have not been approved by Medsafe and will therefore be supplied under Section 29.
They replace the existing section 29 medicines:
- Octreotide MaxRx Inj 50 mcg per ml, 1 ml vial (Pharmacode 2396939)
- Octreotide SUN Inj 500 mcg per ml, 1 ml vial (Pharmacode 2586002).
We will delist these medicines in about 6 months. This allows time for any remaining in the supply chain to be used up.
Who to contact
If you have any questions, contact the Pfizer customer service team on 0800 736 363